Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|July 30, 2024

Prevalence and Staging of Newly Diagnosed Bladder Cancer

Author(s)Mark D. Tyson, MD, MPH, Trinity Bivalacqua, MD, PhD

After briefly introducing themselves, Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss approximately how many newly diagnosed bladder cancer patients have non-muscle invasive bladder cancer, or NMIBC.

Episodes in this series

EP. 1 Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP. 1 Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP. 2 Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP. 2 Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 3 Recurrence and BCG Resistance in High-Risk NMIBC

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 4 Therapies Beyond BCG: FDA-Approved and Emerging Options

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 5 Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 6 CORE-001 Trial Participation and Eligibility Criteria

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 7 Comparing Cretostimogene and BCG Administration Methods

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 8 Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 9 Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 10 Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 11 Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 12 Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Video content above is prompted by the following:

Of patients with newly diagnosed bladder cancer, approximately how many have non-muscle invasive bladder cancer, or NMIBC?
- Can you briefly describe the stages of bladder cancer, and how frequently are patients diagnosed with metastatic disease at time of diagnosis?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

HHS requests testosterone therapy label updates, citing new safety data

Unmet needs and emerging solutions in MRI-guided prostate cancer care

Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD

Microbial dysbiosis may predict response to CBM588 in mRCC

Enzalutamide plus talazoparib demonstrates clinical activity in mHSPC